EUVIMEDOpdag EUVIMED
Übersichtsarbeit

Systems Pharmacology of Human Oncoviruses: Network‐Based Drug Discovery for Virus‐Driven Cancers

Jingyi Sun, Changning Song, Yining Hua, Jiayin Pang, Shuaiting Sun iD

Reviews in Medical Virology · 2026

DOI: 10.1002/rmv.70201 ↗

At a glance

Übersichtsarbeit in Reviews in Medical Virology, 2026. Written by Jingyi Sun and 4 co-authors. Institution: School of Biomedical and Chemical Engineering, Liaoning Institute of Science and Technology, Benxi, China. Major MEDLINE topics: Drug Discovery, Neoplasms, Oncogenic Viruses, Network Pharmacology. 83 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Human oncoviruses, including high‐risk HPV, EBV, HBV, HCV, MCPyV, KSHV, and HTLV‐1, account for approximately 15%–20% of global human malignancies. Rather than acting through isolated pathways, viral oncoproteins systematically rewire host regulatory networks, rendering conventional single‐target oncology paradigms vulnerable to rapid resistance and clinical failure. Systems pharmacology offers a transformative, network‐centric framework that views virus‐driven cancers as systemic perturbations of host protein‐protein interaction networks. This review synthesises computational methodology, network topology, and drug discovery strategies across major human oncoviruses. We examine how graph centrality algorithms, quantitative network proximity metrics (Z‐score), and complementary exposure synergy modelling (S AB ) uncover hidden network vulnerabilities and guide targeted drug repurposing. Despite distinct genomic structures and tissue tropisms, oncogenic viruses converge on shared host interactome hubs, notably TP53, AKT1, BCL2, MYC, STAT3, and VEGFA, to drive cell cycle dysregulation, apoptotic suppression, and microenvironmental remodelling. We evaluate repositioned synthetic pharmaceuticals (such as kinase inhibitors and host ion channel blockers) and multi‐target bioactive formulations, detailing their mechanisms in targeting viral host dependencies. Finally, we address key translational bottlenecks, including disparities between in silico binding predictions and in vivo pharmacokinetics, extensive plasma protein binding, tumour penetration barriers, and viral latency reservoirs. Overcoming these hurdles will require integrating deep graph learning, single‐cell spatial multi‐omics, and patient‐derived organoid models to accelerate the clinical realization of network‐targeted therapies in viral oncology.

Subjects

MeSH terms (MEDLINE)

Drug DiscoveryNeoplasmsOncogenic VirusesNetwork PharmacologyAntiviral AgentsTumor Virus InfectionsHumansProtein Interaction MapsHost-Pathogen InteractionsDrug RepositioningSystems BiologyAntineoplastic Agents

Author keywords

drug repurposinghost‐virus dependenciesinteractome hubsnetwork pharmacologynetwork topologyoncoviruses

Substances

Antiviral AgentsAntineoplastic Agents

Authors and institutions

  • School of Biomedical and Chemical Engineering, Liaoning Institute of Science and Technology, Benxi, China.

ORCID profiles: Shuaiting Sun

Cite

APA

Sun, J., Song, C., Hua, Y., Pang, J., & Sun, S. (2026). Systems Pharmacology of Human Oncoviruses: Network‐Based Drug Discovery for Virus‐Driven Cancers. Reviews in Medical Virology. https://doi.org/10.1002/rmv.70201

Vancouver

Sun J, Song C, Hua Y, Pang J, Sun S. Systems Pharmacology of Human Oncoviruses: Network‐Based Drug Discovery for Virus‐Driven Cancers. Reviews in Medical Virology. 2026. doi:10.1002/rmv.70201

BibTeX
@article{Sun2026,
  author = {Sun, Jingyi and Song, Changning and Hua, Yining and Pang, Jiayin and Sun, Shuaiting},
  title = {Systems Pharmacology of Human Oncoviruses: Network‐Based Drug Discovery for Virus‐Driven Cancers},
  journal = {Reviews in Medical Virology},
  year = {2026},
  doi = {10.1002/rmv.70201}
}
Start for free →